Results of subgroup analyses conducted in this study with subjects diagnosed with PAH associated with connective tissue disease showed improvements in efficacy parameters (6MWD, WHO FC, BDI and NT-proBNP plasma levels) with ambrisentan treatment. Here, NPPB is linked to connective tissue disorder.